Welcome to our dedicated page for Bayer A G news (Ticker: BAYZF), a resource for investors and traders seeking the latest updates and insights on Bayer A G stock.
The BAYZF news page on Stock Titan aggregates recent announcements and press releases related to Bayer AG, a global life science company with core competencies in health care and nutrition. Investors and observers can use this feed to follow how Bayer communicates about its pharmaceutical pipeline, radiology developments, crop science launches and broader corporate strategy.
Recent Bayer news has highlighted updates on its Pharmaceuticals Division, including growth plans built around high-value products and a modality-rich pipeline in oncology, cardiology, neurology, immunology and women’s health. Releases describe pivotal approvals, regulatory milestones, and clinical data from programs in areas such as stroke prevention, heart failure, chronic kidney disease, prostate cancer, lung cancer and menopause-related vasomotor symptoms.
The news flow also covers Bayer’s activities in radiology and molecular imaging, such as clinical results for an investigational low-dose MRI contrast agent and the acquisition of investigational PET and SPECT tracers for diagnosing cardiac amyloidosis. In addition, company communications report collaborations in advanced modalities like cell and gene therapy and siRNA-based treatments, as well as progress in rare kidney diseases including Alport Syndrome.
Beyond human health, Bayer’s crop science releases describe new insecticides and seed treatments for crops such as canola and pulses, illustrating its role in agricultural inputs and food production. Together, these updates provide context on how Bayer pursues its stated mission of “Health for all, Hunger for none” across pharmaceuticals, diagnostics and agriculture. For anyone tracking BAYZF, this news page offers a centralized view of the company’s reported clinical milestones, product launches, partnerships and strategic initiatives over time.
Bayer (OTC: BAYRY) announced a leadership change in its Pharmaceuticals Worldwide Markets organization, appointing Nelson Ambrogio as President of Bayer U.S. Pharmaceuticals effective May 1, 2026. Ambrogio moves from President of global Radiology and will report to Sebastian Guth.
Ambrogio will lead commercial pharmaceutical operations in the U.S., focusing on prostate cancer, cardiovascular care, women’s healthcare and the company’s future secondary stroke prevention portfolio. He will join the Worldwide Markets Leadership Team as Bayer seeks to accelerate U.S. growth.
Bayer Crop Science Canada (OTC:BAYRY) launched Advancing Better Canola (ABCs) on March 26, 2026, an industry initiative to integrate genetics, agronomy, crop protection, and digital tools to support Canadian farmers.
Key commitments: leadership, transparency, and ecosystem empowerment. Bayer announced a $45 million Canola Innovation Centre and investments to build an integrated seed production network in Cranbrook, BC; Lethbridge, AB; and Coaldale, AB.
One A Day (BAYRY) announced a partnership with rapper and actor Ludacris on March 26, 2026, launching the social-first campaign "Health Doesn't Need to Be Ludacris". The campaign uses comedic digital videos to contrast extreme wellness trends with a simple daily multivitamin routine.
It emphasizes One A Day's 80+ years of nutritional science and promotes product selection by age, gender, and life stage, directing consumers to social channels and oneaday.com for more information.
Bayer Crop Science (OTC:BAYRY) launched the 2026 Opportunity Scholarship in Canada to support students entering post‑secondary programs in agriculture, food science, or culinary arts. Twelve scholarships of $5,000 CAD each will be awarded, with preference for two applicants of Canadian Indigenous heritage.
Eligibility requires programs of at least two years at recognized degree or diploma‑granting institutions. The application deadline is May 14, 2026. Full guidelines and application details are available on Bayer Crop Science Canada’s website.
Bayer (NASDAQ: BAYRY) announced that KERENDIA (finerenone) met the primary endpoint in the Phase III FIND-CKD study, showing a statistically significant improvement versus placebo in eGFR slope from baseline to Month 32, a surrogate for slowing kidney disease progression.
This is the fifth consecutive Phase III trial to meet its primary endpoint and the largest Phase III study focused on non-diabetic CKD; Bayer plans to present the data at a scientific conference and anticipates an FDA submission to extend the indication to non-diabetic CKD patients.
Bayer (OTC:BAYRY) announced on March 4, 2026 that the U.S. FDA granted 510(k) clearance expanding the MEDRAD® MRXperion MR Injection System to support MRI scanners up to 7T field strength and adding Imaging Scanner Interface 2 (ISI2) to synchronize injector and scanner workflow.
The clearance aims to broaden MRXperion’s use across routine clinical and advanced research MR environments and strengthens Bayer’s integrated MR portfolio of contrast media, injection systems, software, and workflow solutions.
Bayer (OTC:BAYRY) presented first clinical data for 225Ac-PSMA-Trillium (BAY 3563254), an investigational targeted alpha therapy for advanced metastatic castration-resistant prostate cancer (mCRPC), at the 2026 ASCO Genitourinary Cancers Symposium (Feb 26-28, 2026). The Phase I PAnTHa study identified a dose for expansion with ≥80% PSA50 at that expansion dose, supporting advancement to the next clinical phase. The molecule uses actinium-225 linked to a PSMA-targeting small molecule with an albumin-binding moiety to increase tumor uptake. Data are preliminary and from a first-in-human dose-escalation trial.
Bayer (OTC: BAYRY) reported final PEACE-3 Phase III results showing XOFIGO (radium-223) plus enzalutamide reduced risk of death by 24% (HR 0.76; 95% CI 0.60–0.96; p=0.0096) and extended median overall survival to 38.2 months versus 32.6 months with enzalutamide alone.
The combination also improved radiological progression-free survival (rPFS 19.4 vs. 16.4 months; HR 0.69; p=0.0009). Grade ≥3 treatment-emergent adverse events occurred in 69% vs. 58% of patients. Results presented at ASCO GU 2026 and published simultaneously in Annals of Oncology.
Summary not available.
Bayer (OTC:BAYRY) launched the Heart to Heart Bistro, an immersive dark dining experience with Celebrity Chef Jeff Mauro for American Heart Month on Feb 2026. The campaign ties to the See Your Risks initiative and invites residents of NY, NJ, CT and PA to enter a sweepstakes by completing a 2-minute Heart Health Risk Assessment at SeeYourRisks.com.
The experience uses blindfolded, three-course dining to highlight unseen cardiovascular risk factors and encourage conversations with healthcare professionals.